Diabetes patients taking SGLT2 inhibitors may exhibit false positive urine ethanol tests: NEJM Medha Baranwal9 Feb 2024 11:15 AM ISTUSA: A recent article published in the New England Journal of Medicine described a patient with diabetes who was taking empagliflozin, an SGLT2...
Earlier treatment with SGLT2 inhibitor canagliflozin confers cardiorenal benefits in type 2 diabetes Medha Baranwal7 Feb 2024 10:00 AM ISTCanada: A pooled analysis of the CANVAS Program and CREDENCE trials showed that earlier treatment with canagliflozin confers consistent cardiorenal...
Medical Bulletin 03/February/2024 Anshika Mishra3 Feb 2024 3:00 PM ISTHere are the top medical news of the day:Age-Related Brain Changes and Pain Sensitivity: Impact on Older WomenA new study has found that the brain...
Diabetes medication class tied to lower risk of kidney stones Anshika Mishra3 Feb 2024 9:30 AM ISTRates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones,...
SGLT2 inhibitors use tied to lower risk of kidney stones in patients with type 2 diabetes Medha Baranwal31 Jan 2024 11:15 AM ISTUSA: The use of SGLT2 inhibitors in adults with type 2 diabetes (T2D) may lower nephrolithiasis risk compared with GLP-1 receptor agonists or DPP4...
No need to discontinue SGLT2 inhibitors in response to initial eGFR decline in heart failure patients Medha Baranwal6 Jan 2024 11:00 AM ISTUSA: SGLT2 inhibitors should not be discontinued in response to an initial decline in the estimated glomerular filtration rate (eGFR) among patients...
SGLT2 inhibitors may slow progression of diabetic retinopathy: JAMA Dr. Shravani Dali21 Dec 2023 10:00 PM ISTSGLT2 inhibitors may lower risk of diabetic nephropathy and cut progression of diabetic retinopathy suggests a new study published in the...
SGLT2 inhibitors significantly reduce inflammatory markers like IL-6 alongside blood sugar control Medha Baranwal1 Dec 2023 10:00 AM ISTIran: A recent meta-analysis and systematic review reveals significantly reduced levels of the pro-inflammatory biomarker interleukin-6 (IL-6) with...
Combination of ERA and SGLT2 inhibitor reduced albuminuria in patients with chronic kidney disease: ZENITH-CKD trial Medha Baranwal23 Nov 2023 9:30 AM ISTNetherlands: A combination of zibotentan and dapagliflozin reduced albuminuria with an acceptable safety and tolerability profile, according to phase...
SGLT2 inhibitors failed to improve survival in patients hospitalised with COVID-19 Dr. Kamal Kant Kohli31 Aug 2023 10:00 AM ISTUSA: Findings from a recent study failed to support the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients hospitalized with...
Canagliflozin has no effect on SBP variability and associated CV and renal complications: JAHA Medha Baranwal27 Jun 2023 10:00 AM ISTAustralia: Analysis of participants' data from the CANVAS and CREDENCE Trials revealed that canagliflozin (an SGLT2 inhibitor) has little or no effect...
Dapagliflozin, a feasible alternative to sulphonylureas as an add-on after metformin failure in type 2 diabetes patients Medha Baranwal24 Jun 2023 11:15 AM ISTKorea: Dapagliflozin is safe and well-tolerated and, therefore, appears to be a more favourable alternative to sulphonylureas as an add-on therapy...
